Larimar Therapeutics Inc
LRMR3.460USD
-0.010-0.29%
收盤 11/07, 16:00（美東）報價延遲15分鐘
296.14M總市值
虧損本益比TTM
關於 Larimar Therapeutics Inc 公司
Larimar Therapeutics, Inc. 是一家臨牀階段的生物技術公司。該公司專注於利用其新型細胞穿透肽 (CPP) 技術平臺爲患有複雜罕見疾病的患者開發治療方法。該公司的主要候選產品 nomlabofusp 是一種皮下注射的重組融合蛋白，旨在將一種必需蛋白組織 frataxin (FXN) 輸送到弗裏德賴希共濟失調 (FA) 患者的線粒體。FA 是一種罕見、漸進且致命的疾病，患者由於基因異常無法產生足夠的 FXN。其 CPP 平臺使治療分子能夠穿過細胞膜以達到細胞內靶點，有可能治療其他罕見病和孤兒病。該公司打算利用其專有平臺針對以細胞內內容或活動缺陷或改變爲特徵的其他孤兒適應症。
Larimar Therapeutics Inc簡介
公司代碼LRMR
公司名稱Larimar Therapeutics Inc
上市日期Jun 19, 2014
CEODr. Carole S. Ben-Maimon, M.D.
員工數量65
證券類型Ordinary Share
年結日Jun 19
公司地址Three Bala Plaza East. Suite 506
城市BALA CYNWYD
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編19004
電話18445119056
網址https://larimartx.com/
公司代碼LRMR
上市日期Jun 19, 2014
CEODr. Carole S. Ben-Maimon, M.D.
Larimar Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas Edward Hamilton
Mr. Thomas Edward Hamilton
Independent Director
Independent Director
590.81K
-18.42%
Dr. Carole S. Ben-Maimon, M.D.
Dr. Carole S. Ben-Maimon, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
180.86K
-11.38%
Mr. Michael (Mike) Celano
Mr. Michael (Mike) Celano
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
82.56K
-8.20%
Dr. Russell G. (Rusty) Clayton, Sr.
Dr. Russell G. (Rusty) Clayton, Sr.
Chief Medical Officer
Chief Medical Officer
45.81K
+103.58%
Dr. Gopi Shankar, Ph.D.
Dr. Gopi Shankar, Ph.D.
Chief Development Officer
Chief Development Officer
10.63K
-62.46%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Director
Independent Director
2.00K
--
Mr. Joseph (Joe) Truitt
Mr. Joseph (Joe) Truitt
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas Edward Hamilton
Mr. Thomas Edward Hamilton
Independent Director
Independent Director
590.81K
-18.42%
Dr. Carole S. Ben-Maimon, M.D.
Dr. Carole S. Ben-Maimon, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
180.86K
-11.38%
Mr. Michael (Mike) Celano
Mr. Michael (Mike) Celano
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
82.56K
-8.20%
Dr. Russell G. (Rusty) Clayton, Sr.
Dr. Russell G. (Rusty) Clayton, Sr.
Chief Medical Officer
Chief Medical Officer
45.81K
+103.58%
Dr. Gopi Shankar, Ph.D.
Dr. Gopi Shankar, Ph.D.
Chief Development Officer
Chief Development Officer
10.63K
-62.46%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Director
Independent Director
2.00K
--
收入明細
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States (Country)
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 11月1日 週六
更新時間: 11月1日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Deerfield Management Company, L.P.
35.76%
RA Capital Management, LP
7.06%
Millennium Management LLC
5.80%
Blue Owl Capital Holdings LP
5.76%
Opaleye Management Inc.
4.80%
其他
40.81%
持股股東
持股股東
佔比
Deerfield Management Company, L.P.
35.76%
RA Capital Management, LP
7.06%
Millennium Management LLC
5.80%
Blue Owl Capital Holdings LP
5.76%
Opaleye Management Inc.
4.80%
其他
40.81%
股東類型
持股股東
佔比
Hedge Fund
56.79%
Investment Advisor
13.99%
Venture Capital
7.26%
Investment Advisor/Hedge Fund
4.32%
Individual Investor
1.07%
Research Firm
0.97%
Private Equity
0.91%
Family Office
0.07%
Bank and Trust
0.06%
其他
14.56%
機構持股
更新時間: 10月5日 週日
更新時間: 10月5日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
246
72.22M
84.38%
+2.35M
2025Q2
237
70.20M
94.16%
-3.03M
2025Q1
241
65.66M
102.55%
-8.64M
2024Q4
237
68.11M
106.77%
-7.20M
2024Q3
225
68.88M
107.96%
-7.04M
2024Q2
207
69.87M
109.52%
-2.95M
2024Q1
185
68.09M
106.93%
+8.87M
2023Q4
161
43.68M
97.08%
-3.08M
2023Q3
157
39.54M
87.67%
-8.23M
2023Q2
151
39.82M
92.04%
-2.98M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Deerfield Management Company, L.P.
30.61M
35.76%
+9.38M
+44.16%
Jul 31, 2025
RA Capital Management, LP
6.05M
7.06%
--
--
Jun 30, 2025
Millennium Management LLC
3.66M
4.27%
+2.98M
+443.11%
Jun 30, 2025
Blue Owl Capital Holdings LP
4.93M
5.76%
+150.00K
+3.14%
Jun 30, 2025
Opaleye Management Inc.
4.11M
4.8%
--
--
Aug 29, 2025
The Vanguard Group, Inc.
2.14M
2.5%
-75.78K
-3.42%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.75M
3.21%
-90.21K
-3.18%
Jun 30, 2025
Alyeska Investment Group, L.P.
2.08M
2.43%
+633.41K
+43.91%
Jun 30, 2025
Two Sigma Investments, LP
2.05M
2.4%
+1.26M
+159.97%
Jun 30, 2025
Citadel Advisors LLC
1.34M
1.56%
+901.97K
+207.69%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
0.29%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Biotechnology ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
iShares Neuroscience and Healthcare ETF
佔比0.29%
iShares Micro-Cap ETF
佔比0.03%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
Avantis US Small Cap Equity ETF
佔比0.02%
ProShares UltraPro Russell2000
佔比0.01%
iShares Russell 2000 Value ETF
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
May 28, 2020
Merger
12→1
May 28, 2020
Merger
12→1
May 28, 2020
Merger
12→1
May 28, 2020
Merger
12→1
公告日期
類型
比率
May 28, 2020
Merger
12→1
May 28, 2020
Merger
12→1
May 28, 2020
Merger
12→1
May 28, 2020
Merger
12→1
